Genmab A/S American Depositary Shares (GE91)
XFRA 
Summary
GE91 Chart
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Presentation Benjamin Jackson Jefferies LLC, Research Division Good to see you all here. Welcome to day 3 of the Jefferies London Healthcare Conference.
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2025 Earnings Call November 6, 2025 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental Medicines Brad Bailey Anthony Pagano - Executive VP & CFO Judith Klimovsky - Executive VP & Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Xian Deng - UBS Investment Bank, Research Division Qize Ding - Rothschild & Co Redburn, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Victor Floch - BNP Paribas, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Charlie Haywood - BofA Securities, Research Division Presentation Operator Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call.
Genmab A/S American Depositary Shares (GE91) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Genmab A/S American Depositary Shares ever had a stock split?
Genmab A/S American Depositary Shares Profile
| - Industry | - Sector | Jan G.J. van de Winkel CEO | XFRA Exchange | US3723032062 ISIN |
| DK Country | 2,638 Employees | - Last Dividend | 1 May 2018 Last Split | - IPO Date |
Overview
Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, specializing in the development of antibody therapeutics for the treatment of cancer and other serious diseases. Founded in 1999, Genmab has grown to become a leader in the field, leveraging its expertise to market innovative treatments worldwide. The company's therapeutic products focus on employing human monoclonal antibodies to target and combat diseases, with a strong emphasis on hematological malignancies and solid tumors. Genmab's strategic collaborations with industry leaders like Seagen Inc., argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S play a pivotal role in expanding its portfolio and enhancing therapeutic development.
Products and Services
- DARZALEX: A human monoclonal antibody indicated for the treatment of patients with multiple myeloma (MM), DARZALEX has shown significant efficacy in improving patient outcomes.
- Teprotumumab: This therapeutic agent is used for the treatment of thyroid eye disease, showcasing Genmab's ability to address rare and severe conditions.
- Amivantamab: Designed for patients with advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC), Amivantamab illustrates Genmab's focus on solid tumors.
- Daratumumab: Beyond its use in MM treatment, daratumumab is explored for non-MM blood cancers and AL amyloidosis, underscoring its versatile potential in hematological conditions.
- GEN1047, Tisotumab Vedotin, DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, Epcoritamab, HexaBody-CD38, and GEN3017: These diverse therapeutic candidates are at various stages of development for treating conditions such as cervical, ovarian, and solid cancers, hematological malignancies, relapsed/refractory diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Each represents Genmab's commitment to expanding its portfolio across a wide range of cancers.
- Inclacumab: Currently in a Phase 3 trial for vaso-occlusive crises, Inclacumab exemplifies Genmab's venture into non-cancerous disorders, providing potential new treatments for conditions with substantial unmet needs.
- Camidanlumab Tesirine: A candidate for treating Hodgkin lymphoma and solid tumors, highlighting the company's ongoing efforts in targeting both hematologic cancers and solid tumors.
- JNJ-64007957 and JNJ-64407564: These antibodies are in development for multiple myeloma treatment, illustrating ongoing innovation in this challenging therapeutic area.
- PRV-015: For treating celiac disease, PRV-015 demonstrates Genmab's ability to apply its antibody expertise beyond oncology, addressing autoimmune conditions.
- Mim8: A candidate for hemophilia A treatment, showcasing Genmab's commitment to improving the quality of life for patients with blood disorders.
- Lu AF82422: In development for multiple system atrophy disease, Lu AF82422 represents Genmab's research into neurodegenerative disorders, expanding the company's therapeutic reach.
Contact Information
